Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
82.82 EUR | -2.56% | +4.34% | +37.71% |
02/04 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
12/03 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+37.71% | 4.7B | B+ | ||
+25.83% | 661B | C+ | ||
+26.60% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+14.75% | 231B | B+ | ||
+5.41% | 200B | B- | ||
-8.88% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROVI Stock
- Ratings Laboratorios Farmaceuticos Rovi, S.A.